|
| 37584176 | The Patient-Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis. | | 2024 |
| 37541839 | Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis. | | 2023 |
| 35894247 | Prediction of relapse activity when switching to cladribine for multiple sclerosis. | Multiple Sclerosis Journal | 2023 |
| 36434910 | Long-term dietary acid load is associated with depression in multiple sclerosis, but less evidence was found with fatigue and anxiety. | Multiple Sclerosis and Related Disorders | 2023 |
| 36433775 | Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. | Multiple Sclerosis Journal | 2023 |
| 36395524 | Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate. | Neuroradiology Journal | 2023 |
| 36448302 | Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity. | Brain | 2023 |
| 38039696 | Is multiple sclerosis a glymphaticopathy? | | 2023 |
| 37738709 | Are we there yet? The holy grail: A biomarker for Multiple Sclerosis. | | 2023 |
| 37582327 | Is it ethical to use teriflunomide as an active comparator in phase 3 trials? | | 2023 |
| 38085047 | Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. | | 2023 |
| 37978852 | Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. | | 2023 |
| 37634271 | CNS resilience in the progression of MS. | | 2023 |
| 37628757 | DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes. | Int J Mol Sci | 2023 |
| 37871481 | Can we improve outcomes in MS around the world? Access and global considerations across income strata. | | 2023 |
| 37683558 | Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective. | | 2023 |
| 37479377 | Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. | Lancet Neurol | 2023 |
| 37414534 | Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. | | 2023 |
| 37287269 | A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. | | 2023 |
| 37216723 | Equity, diversity and inclusion in academic publishing: Can we move the needle? | | 2023 |
| 37148166 | A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study. | | 2023 |
| 37463930 | The association between disability progression, relapses, and treatment in early relapse onset MS: an observational, multi-centre, longitudinal cohort study. | | 2023 |
| 37273217 | Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. | | 2023 |
| 36765422 | Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis. | | 2023 |
| 37270888 | Migraine and multiple sclerosis: The final answer? | | 2023 |
| 36636583 | The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis. | | 2023 |
| 37325639 | Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis. | | 2023 |
| 37321380 | CEST 2022 - Differences in APT-weighted signal in T1 weighted isointense lesions, black holes and normal-appearing white matter in people with relapsing-remitting multiple sclerosis. | | 2023 |
| 37321377 | Fast WASABI post-processing: Access to rapid B and B correction in clinical routine for CEST MRI. | | 2023 |
| 37068931 | Disability accrual in primary and secondary progressive multiple sclerosis. | | 2023 |
| 36696700 | Cancer risk and mortality in multiple sclerosis: The need for vigilance. | | 2023 |
| 37442078 | Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022. | | 2023 |
| 36800908 | Comparative effectiveness in multiple sclerosis: A methodological comparison. | | 2023 |
| 36746088 | Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity. | | 2023 |
| 36692895 | Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. | | 2023 |
| 37437240 | Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. | | 2023 |
| 37369086 | The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. | | 2023 |
| 37307006 | Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. | | 2023 |
| 36931080 | Multiple types of relapses in MOG antibody disease. | | 2023 |
| 36863220 | Are we ready for CD19-targeted CAR T-cell therapies in MS? | | 2023 |
| 37295263 | Beyond the B-cell as a treatment target in multiple sclerosis. | | 2023 |
| 36990053 | Inequality in accessing healthcare for people with MS. | | 2023 |
| 37356258 | Dilatation of the bridging cerebral veins in multiple sclerosis correlates with fatigue and suggests an increase in pressure. | | 2023 |
| 37352902 | Conceiving complexity: Biological mechanisms underpinning the lasting effect of pregnancy on multiple sclerosis outcomes. | | 2023 |
| 36851894 | Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. | | 2023 |
| 37542923 | Higher dietary quality is prospectively associated with lower MRI FLAIR lesion volume, but not with hazard of relapse, change in disability or black hole volume in people with Multiple Sclerosis. | | 2023 |
| 34749246 | Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]. | Comput Methods Programs Biomed | 2022 |
| 36183565 | Linking X to MS: Immunity and demyelination on the X-chromosome in MS. | Multiple Sclerosis and Related Disorders | 2022 |
| 35714573 | Multiple sclerosis is one disease. | Multiple Sclerosis and Related Disorders | 2022 |
| 36369345 | Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosis. | Scientific Reports | 2022 |